Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.73 |
| ▸ | TENT4A | Q5XG87 | 1/20 | 0.73 |
| ▸ | TENT4B | Q8NDF8 | 1/20 | 0.73 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16942404 | 1.00 | CYP2B6 (0.73) | CYP2B6TENT4ATENT4BHTR1AHTR2A | |
| SCHEMBL16942409 | 1.00 | CYP2B6 (0.73) | CYP2B6TENT4ATENT4BHTR1AHTR2A | |
| SCHEMBL16929853 | 1.00 | CYP2B6 (0.73) | CYP2B6TENT4ATENT4BHTR1AHTR2A | |
| SCHEMBL19924549 | 1.00 | CYP2B6 (0.73) | CYP2B6TENT4ATENT4BHTR1AHTR2A | |
| SCHEMBL16930014 | 0.98 | CYP2B6 (0.71) | CYP2B6TENT4ATENT4BHTR1AHTR2A | |
| SCHEMBL16929883 | 0.95 | CYP2B6 (0.67) | CYP2B6TENT4ATENT4B | |
| SCHEMBL16942415 | 0.95 | CYP2B6 (0.67) | CYP2B6TENT4ATENT4B | |
| SCHEMBL16942414 | 0.95 | CYP2B6 (0.67) | CYP2B6TENT4ATENT4B | |
| SCHEMBL16929909 | 0.93 | CYP2B6 (0.63) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21043364 | 0.93 | CYP2B6 (0.73) | CYP2B6TENT4ATENT4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715624-B | Novel therapeutic agents for the treatment of HBV infection | 广州麓鹏制药有限公司 | 2022-08-16 | — | — | CN | disclosed |